Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GALR1 | P47211 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27173374 | 0.94 | HTR2C (0.56) | HTR2CSERPINE1CHRNB4CHRNA3ACMSD | |
| SCHEMBL31632210 | 0.94 | HTR2C (0.56) | HTR2CSERPINE1CHRNB4CHRNA3ACMSD | |
| SCHEMBL9377713 | 0.86 | HTR2C (0.62) | HTR2CCHRNB4CHRNA3ALOX5IDO1 | |
| SCHEMBL14705031 | 0.79 | HTR2C (0.73) | HTR2CIDO1 | |
| SCHEMBL28603570 | 0.78 | HTR2C (0.54) | HTR2CCHRNB4CHRNA3ALOX5IDO1 | |
| SCHEMBL14704909 | 0.78 | HTR2C (0.82) | HTR2CCHRNB4CHRNA3 | |
| SCHEMBL511919 | 0.77 | SIGMAR1 (0.50) | HTR2CSERPINE1ACMSD | |
| SCHEMBL968176 | 0.77 | CHRNB4 (0.46) | SERPINE1CHRNB4CHRNA3ACMSDIDO1 | |
| SCHEMBL6182740 | 0.77 | ACMSD (0.42) | HTR2CSERPINE1ACMSD | |
| SCHEMBL18905493 | 0.77 | ACMSD (0.42) | HTR2CSERPINE1ACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | HTR2C 1079/4885SERPINE1 961/4885CHRNB4 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.